{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:49:39Z","timestamp":1791269379233,"version":"4.1.0"},"reference-count":19,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, has recently been approved as a biological therapy for rheumatoid arthritis (RA) and other diseases. It is not known if there are characteristic changes in gene expression and immunoglobulin G glycosylation during therapy or in response to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Global gene expression profiles from peripheral blood mononuclear cells of 13 patients with RA and active disease at Week 0 (baseline) and Week 4 following treatment were obtained together with clinical measures, serum cytokine levels using ELISA, and the degree of galactosylation of the IgG N-glycan chains. Gene sets separating responders and nonresponders were tested using canonical variates analysis. This approach also revealed important gene groups and pathways that differentiate responders from nonresponders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Fifty-nine genes showed significant differences between baseline and Week 4 and thus correlated with treatment. Significantly, 4 genes determined responders after correction for multiple testing. Ten of the 12 genes with the most significant changes were validated using real-time quantitative polymerase chain reaction. An increase in the terminal galactose content of N-linked glycans of IgG was observed in responders versus nonresponders, as well as in treated samples versus samples obtained at baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>As a preliminary report, gene expression changes as a result of tocilizumab therapy in RA were examined, and gene sets discriminating between responders and nonresponders were found and validated. A significant increase in the degree of galactosylation of IgG N-glycans in patients with RA treated with tocilizumab was documented.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.110961","type":"journal-article","created":{"date-parts":[[2012,4,2]],"date-time":"2012-04-02T00:15:04Z","timestamp":1333325704000},"page":"916-928","source":"Crossref","is-referenced-by-count":27,"title":["Peripheral Blood Gene Expression and IgG Glycosylation Profiles as Markers of Tocilizumab Treatment in Rheumatoid Arthritis"],"prefix":"10.3899","volume":"39","author":[{"given":"BERTALAN","family":"MESKO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SZILARD","family":"POLISKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SZILVIA","family":"SZAMOSI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZOLTAN","family":"SZEKANECZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JANOS","family":"PODANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CSABA","family":"VARADI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDRAS","family":"GUTTMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LASZLO","family":"NAGY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2012,4,1]]},"reference":[{"key":"2018112909274941000_39.5.916.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"2018112909274941000_39.5.916.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep329"},{"key":"2018112909274941000_39.5.916.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0953-0"},{"key":"2018112909274941000_39.5.916.4","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969050-00007"},{"key":"2018112909274941000_39.5.916.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.20303"},{"key":"2018112909274941000_39.5.916.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"2018112909274941000_39.5.916.7","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-3-15"},{"key":"2018112909274941000_39.5.916.8","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.27415","article-title":"Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood","volume":"62","author":"van Baarsen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2018112909274941000_39.5.916.9","doi-asserted-by":"publisher","DOI":"10.1038\/415530a"},{"key":"2018112909274941000_39.5.916.10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1172\/JCI115643","article-title":"Changes in normal glycosylation mechanisms in autoimmune rheumatic disease","volume":"89","author":"Axford","year":"1992","journal-title":"J Clin Invest"},{"key":"2018112909274941000_39.5.916.11","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20191"},{"key":"2018112909274941000_39.5.916.12","unstructured":"Podani J . Introduction to the exploration of multivariate biological data. Leiden: Backhuys; 2000."},{"key":"2018112909274941000_39.5.916.13","unstructured":"Podani J . Syn-Tax 2000 computer programs for data analysis in ecology and systematics. User\u2019s manual. Budapest: Scientia; 2001."},{"key":"2018112909274941000_39.5.916.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken083"},{"key":"2018112909274941000_39.5.916.15","doi-asserted-by":"publisher","DOI":"10.1007\/BF00731321"},{"key":"2018112909274941000_39.5.916.16","first-page":"277","article-title":"Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results","volume":"10","author":"Braun-Moscovici","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"2018112909274941000_39.5.916.17","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328331b53e"},{"key":"2018112909274941000_39.5.916.18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/QAD.0b013e32832605e6","article-title":"Highly restricted T-cell receptor repertoire in the CD8+ T-cell response against an HIV-1 epitope with a stereotypic amino acid substitution","volume":"23","author":"Miyazaki","year":"2009","journal-title":"AIDS"},{"key":"2018112909274941000_39.5.916.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01110.x"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.110961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T19:14:29Z","timestamp":1641928469000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.110961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,1]]},"published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.3899\/jrheum.110961"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.110961","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,1]]}}}